Anxiety Disorders and Depression Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Antidepressants, Anxiolytics, Anticonvulsants, Noradrenergic Agents, and Atypical Antipsychotics), By Indication (Anxiety and Depression), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027

 ATTRIBUTE

  DETAILS

Study Period

  2016-2027

Base Year

  2019

Forecast Period

  2020-2027

Historical Period

  2016-2018

Unit

  Value (USD Billion)

Segmentation

  Drug Class; Indication; Distribution Channel; and Region

By Drug Class

• Antidepressants
• Anxiolytics
• Anticonvulsants
• Noradrenergic Agents
• Atypical Antipsychotics

By Indication

• Anxiety
• Depression

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (Drug Class; Indication; Distribution Channel)
  • USA (By Indication)
  • Canada (By Indication)
• Europe (Drug Class; Indication; Distribution Channel)
  • The U.K. (By Indication)
  • Germany (By Indication)
  • France (By Indication)
  • Italy (By Indication)
  • Spain (By Indication)
  • Scandinavia (By Indication)
  • Rest of Europe (By Indication)
• Asia Pacific (Drug Class; Indication; Distribution Channel)
  • Japan (By Indication)
  • China (By Indication)
  • India (By Indication)
  • Australia (By Indication)
  • Southeast Asia (By Indication)
  • Rest of Asia Pacific (By Indication)
• Latin America (Drug Class; Indication; Distribution Channel)
  • Brazil (By Indication)
  • Mexico (By Indication)
  • Rest of Latin America (By Indication)
• The Middle East & Africa (Drug Class; Indication; Distribution Channel)
  • GCC (By Indication)
  • South Africa (By Indication)
  • Rest of Middle East & Africa (By Indication)